- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 3
The Center for Biosimilars® recaps the top news for the week of September 3, 2018.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 3.
Number 5: A newly published study in pediatric patients with Crohn disease found that infliximab improved clinical outcome measures from week 2 to week 56.
Number 4: New Zealand’s cost control agency has proposed to stop funding Janssen’s epoetin alfa in favor of funding Novartis’ biosimilar.
Number 3: New research shows that patients may be paying more out of pocket for biosimilar infliximab, and that the advent of biosimilar filgrastim has not expanded access.
Number 2: Celltrion is asking the United Kingdom to lower its threshold to provide access to biologic drugs for patients with rheumatoid arthritis.
Number 1: The FDA heard from 27 speakers, from across the spectrum of stakeholders, at its public hearing on the Biosimilar Action Plan.
Finally, last week, our e-newsletter asked whether you think that the FDA should do away with its current guidance on biosimilar suffixes.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
